COMMUNIQUÉS West-GlobeNewswire

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update
29/06/2026
WOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial [...]
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
29/06/2026
Optimi’s 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression. The export marks Optimi’s third commercial shipment since launching the 5mg psilocybin capsules in September 2025. [...]
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
29/06/2026
Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise SOUTH SAN FRANCISCO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage [...]
IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper
29/06/2026
Key member of management ranks at top 2% of researchers in the field of laboratory diagnostics and top 2.5% of all researchers worldwide, based on H-index of 58 Recent studies advanced science of molecular diagnostic [...]
Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
29/06/2026
ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe First patient enrollment anticipated in the second half of 2026; primary efficacy [...]
Cannabix Technologies Announces First BreathLogix Alcohol Device Deployment to West Africa for Mining Sector
29/06/2026
VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices, is [...]
SPR Wins Fifth Consecutive Northeast Ohio Top Workplaces Award
29/06/2026
CLEVELAND, Ohio, June 29, 2026 (GLOBE NEWSWIRE) -- SPR has been recognized as a Top Workplace by Northeast Ohio Top Workplaces for the fifth consecutive year, marking a significant milestone that reflects the impact of [...]
New Video Series “Ahead of Alzheimer’s” Launches Focused on a Renewed Look at Early Alzheimer’s Detection and Preventive Brain Health Care
29/06/2026
WASHINGTON, June 29, 2026 (GLOBE NEWSWIRE) -- A new video series focused on making brain health and Alzheimer’s detection a standard part of preventive care launches today on YouTube and Substack . Ahead of Alzheimer's [...]
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
29/06/2026
LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing Topics [...]
New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome
29/06/2026
Clinically meaningful improvements in skin symptoms reported as early as week 4 and sustained over the 48-week study period Data presented at the 6th World Congress of Cutaneous Lymphomas meeting in Montreal, Canada [...]
Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial
29/06/2026
Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial IRVINE, California – [...]
Achieve Life Sciences Joins Russell 2000® Index
29/06/2026
SEATTLE and VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global [...]
Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026
29/06/2026
First-in-Human Results Demonstrate Favorable Safety and Pharmacokinetics Profile AI Aided Target Engagement Research Advancing Development of Novel Biomarkers SOLANA BEACH, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- [...]
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
29/06/2026
4FRONT-2 global enrollment completed approximately 4 months ahead of initial projections 4FRONT-2 over-enrolled (anticipated N>500), with final patient randomization expected in Q3 2026, reflecting strong interest [...]
HealthLynked Launches AI-Powered Healthcare Communication Platform Featuring 24/7 Appointment Scheduling and Medical Office AI Agents
29/06/2026
NAPLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- via IBN – HealthLynked Corp. (OTCQB: HLYK ), a leader in healthcare technology, patient engagement, and care coordination, today announced the launch of its next- [...]
Novo Nordisk A/S - share repurchase programme
29/06/2026
Bagsværd, Denmark, 29 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
TOMI Environmental Solutions Announces Definitive Agreement to Merge with Carbonium Core
29/06/2026
Transaction will create a public market pure-play on America's nuclear renaissance, positioned at the intersection of AI-driven power demand, advanced nuclear reactors, and domestic critical materials production [...]
Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones
29/06/2026
Consolidated closing of recently announced $5.5 million PIPE led by existing investors, combined with an additional $2.8 million in proceeds from warrant exercises, results in approximately $8.3 million of capital [...]
Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
29/06/2026
BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, [...]

Pages